EMA accepts Takeda's submission of diabetes drug alogliptin

Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502), says its European subsidiary has received confirmation of the acceptance of the submission of a Marketing Authorization Application from the European Medicines Agency for alogliptin, a selective dipeptidyl peptidase IV inhibitor (DPP-4i) for the treatment of type 2 diabetes.

Takeda previously postponed its MAA for alogliptin (SYR-322) and the fixed dose combination of alogliptin and pioglitazone (SYR-322-4833), originally planned for mid-2009, as it is initiating a long-term trial for the type 2 diabetes drugs.

"The acceptance of the alogliptin MAA submission is a critical milestone for Takeda as we continue investigating and expanding our therapeutic offerings for people with type 2 diabetes," said Stuart Dollow, managing director, Takeda Global Research & Development Centre (Europe), adding: "As type 2 diabetes is an increasing global issue, our commitment includes expanding across the globe to reach a wider patient population who could benefit from new treatments."